<DOC>
	<DOC>NCT02121483</DOC>
	<brief_summary>The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: Children and adolescents with type 2 diabetes mellitus Insufficient glycaemic control (HbA1c &lt;=10.5%) despite diet and exercise and/or metformin and/or stable basal or MDI insulin Negative for Islet Cell Antigen and Glutamic Acid Decarboxylase autoantibodies and fasting Cpeptide levels &gt;= 0.85 ng/ml BMI &gt; 50th percentile for age and sex Exclusion criteria: Uncontrolled hyperglycaemia with a glucose level &gt; 240 mg/dl (&gt; 13.3 mmol/l) History of acute metabolic decompensation such as diabetic ketoacidosis within 3 months before the screening visit with the exception of acute decompensation at the time of type 2 diabetes diagnosis Treatment with weight reduction medications within 4 weeks before randomisation</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>